Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

New Johns Hopkins study finds occurrence of gonorrhea or chlamydia is significant in women

Current public health guidelines recommend that only gay men and people with HIV should be routinely screened for extragenital gonorrhea and chlamydia, given the high burden of these sexually transmitted infections (STIs) in this at-risk population.

29 Apr 2015

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex Corporation today announced that testing at the clinical trial sites for the ARIES HSV 1&2 Assay is now complete. The next steps, including site to site reproducibility testing, followed by data analysis and assembly of the data package for submission to the FDA, are now underway.

From Luminex 28 Apr 2015

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, today announced the presentation of data demonstrating the promise of its lead clinical candidate, TXA709, in combating antibiotic resistance.

27 Apr 2015

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented in two posters at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), on April 25, 2015, in Copenhagen, Denmark.

27 Apr 2015

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Nearly half of American hospitals aren't taking key steps to prevent a kind of gut infection that kills nearly 30,000 people annually and sickens hundreds of thousands more - despite strong evidence that such steps work, according to a new study.

25 Apr 2015

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis plc today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA).

25 Apr 2015

Leading scientists warn of 'Antibiotic Armageddon' in Britain and Europe by 2025

A group of leading scientists has warned that Britain and Europe collectively could face more than a million deaths in an impending "Antibiotic Armageddon” unless more is spent on developing new cures, rapid diagnostics and preventative measures to combat the spread of drug resistant diseases.

24 Apr 2015

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai.

24 Apr 2015

Alltech enters into agreement to acquire Ridley

Alltech and Ridley Inc. announced today that they have entered into a plan of arrangement agreement under which Alltech will acquire 100 percent of the outstanding stock of Ridley, one of the leading commercial animal nutrition companies in North America, for CAD $40.75 per share.

23 Apr 2015

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far.

23 Apr 2015

Rising shortages of key antibiotics raise serious concerns about effects on patient care

Shortages of key antibiotics, including gold-standard therapies and drugs used to treat highly resistant infections, are on the rise, according to a new study of shortages from 2001 to 2013 published in Clinical Infectious Diseases and available online. The trends raise serious concerns about the effects on patient care, particularly for infections without effective alternative treatment options.

23 Apr 2015

Study finds increasing size of elderly population as major contributor to TB infection in China

22 Apr 2015

Gene therapy reduces infectious complications in children, teens with Wiskott-Aldrich syndrome

In a small study that included seven children and teens with Wiskott-Aldrich syndrome, a rare immunodeficiency disorder, use of gene therapy resulted in clinical improvement in infectious complications, severe eczema, and symptoms of autoimmunity, according to a study in the April 21 issue of JAMA, a theme issue on child health.

22 Apr 2015

Winners of GSA poster awards announced at Fungal Genetics Conference

The Genetics Society of America and the community of fungal geneticists are pleased to announce the winners of the GSA poster awards at the 28th Fungal Genetics Conference, which took place in Pacific Grove, CA, March 17-22, 2015.

22 Apr 2015

UCLA-led stroke study selected as one of 10 most outstanding research papers by CRF

A UCLA-led study on improving stroke care was selected by the Clinical Research Forum (CRF) as one of the 10 most outstanding research papers written by teams from across the nation in 2014. The organization highlighted the papers at its fourth annual awards ceremony in Washington, D.C. on April 16.

21 Apr 2015

Lupin introduces first Brand product Zaxine in Canada

Pharma Major Lupin Limited announced today that its Canadian subsidiary, Lupin Pharma Canada Limited (collectively Lupin) has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina based GI specialty company Salix Pharmaceuticals Inc.

20 Apr 2015

New Commission outlines current state of research into sepsis

Leading doctors today [Monday 20 April, 2015] warn that medical and public recognition of sepsis--thought to contribute to between a third and a half of all hospital deaths--must improve if the number of deaths from this common and potentially life-threatening condition are to fall.

20 Apr 2015

Maple syrup makes disease-causing bacteria more susceptible to antibiotics, study shows

A concentrated extract of maple syrup makes disease-causing bacteria more susceptible to antibiotics, according to laboratory experiments by researchers at McGill University.

17 Apr 2015

More personalized treatment protocols can reduce mortality in cancer patients with severe pneumonia

Cancer patients are more likely to get infections. Pneumonia is the most frequent type of infection in this group and a frequent cause of ICU admission and mortality. A study conducted by researchers from the D'Or Institute for Research and Education in partnership with Brazilian hospitals and universities analyzed the factors associated with severe pneumonia in hospitalized cancer patients and suggests that more personalized treatment protocols can reduce mortality in these patients.

13 Apr 2015

Infectious diseases experts release new guidance to avoid infections during hospital visits

Leading infectious diseases experts have released new guidance for healthcare facilities looking to establish precautions for visitors of patients with infectious diseases. The guidance looks to reduce the potential for healthcare visitors in spreading dangerous bacteria within the healthcare facility and community.

13 Apr 2015

Antibiotic News and Research

Further Reading

New Johns Hopkins study finds occurrence of gonorrhea or chlamydia is significant in women

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Leading scientists warn of 'Antibiotic Armageddon' in Britain and Europe by 2025

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

Alltech enters into agreement to acquire Ridley

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Rising shortages of key antibiotics raise serious concerns about effects on patient care

Study finds increasing size of elderly population as major contributor to TB infection in China

Gene therapy reduces infectious complications in children, teens with Wiskott-Aldrich syndrome

Winners of GSA poster awards announced at Fungal Genetics Conference

UCLA-led stroke study selected as one of 10 most outstanding research papers by CRF

Lupin introduces first Brand product Zaxine in Canada

New Commission outlines current state of research into sepsis

Maple syrup makes disease-causing bacteria more susceptible to antibiotics, study shows

More personalized treatment protocols can reduce mortality in cancer patients with severe pneumonia

Infectious diseases experts release new guidance to avoid infections during hospital visits

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News